Multi-omics liquid biospy specialist Freenome Inc. has baged US$254m in a financing round led by Roche AG to fund early cancer detection in 6,200 patients using its AI-guided cancer detection platform.
ADVERTISEMENT
ADVERTISEMENT
Log in here to read the desired article.
ADVERTISEMENT
Multi-omics liquid biospy specialist Freenome Inc. has baged US$254m in a financing round led by Roche AG to fund early cancer detection in 6,200 patients using its AI-guided cancer detection platform.